In addition, different methods of staining and scoring, such as the use of different positivity thresholds, have contributed to variable conclusions regarding the role of tumor PD-L1 expression as a biomarker predictive of response to anti-PD-1-based therapies. This evidence concerns the gene CD274 and neoplasm.